---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-036979"
form_type: "8-K"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2026-08-11T11:05:26+00:00"
generated_at: "2026-08-11T11:10:32.598963+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Xtant Q2 revenue down 35% to $23M, net loss $9.4M, cuts FY guidance

## Summary
- Revenue $23.0M vs $35.4M YoY; net loss $9.4M vs income $3.6M.
- Adjusted EBITDA loss $2.7M vs +$6.9M; gross margin 57.9% vs 68.6%.
- FY2026 revenue guidance cut to $99-103M from $101-105M.
- Exclusive U.S. distribution deal with Dilon for HEMOBLAST Bellows; hired ~20-person sales team.
- Cash $9.9M, debt $23.0M, revolver availability $0.7M as of June 30, 2026.

## SEC filing metadata
- accession: 0001493152-26-036979
- form_type: 8-K
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2026-08-11T11:05:26+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000149315226036979/0001493152-26-036979-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000149315226036979/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-036979
- JSON: https://secwatch.observer/filing/0001493152-26-036979.json
- Plain text: https://secwatch.observer/filing/0001493152-26-036979.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.